Related references
Note: Only part of the references are listed.Celastrol induces lipophagy via the LXRα/ABCA1 pathway in clear cell renal cell carcinoma
Chan-juan Zhang et al.
ACTA PHARMACOLOGICA SINICA (2021)
Gut-liver axis modulation of Panax notoginseng saponins in nonalcoholic fatty liver disease
Yu Xu et al.
HEPATOLOGY INTERNATIONAL (2021)
Celastrol in metabolic diseases: Progress and application prospects
Shaohua Xu et al.
PHARMACOLOGICAL RESEARCH (2021)
Nanotechnology-Based Celastrol Formulations and Their Therapeutic Applications
Pushkaraj Rajendra Wagh et al.
FRONTIERS IN PHARMACOLOGY (2021)
Nonalcoholic Fatty Liver Disease: Pathogenesis and Treatment in Traditional Chinese Medicine and Western Medicine
Tingting Shi et al.
EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE (2020)
Epidemiology of non-alcoholic and alcoholic fatty liver diseases
Souveek Mitra et al.
TRANSLATIONAL GASTROENTEROLOGY AND HEPATOLOGY (2020)
Modulation of Lipid Metabolism by Celastrol
Ting Zhang et al.
JOURNAL OF PROTEOME RESEARCH (2019)
Celastrol-loaded PEG-PCL nanomicelles ameliorate inflammation, lipid accumulation, insulin resistance and gastrointestinal injury in diet-induced obese mice
Jia Zhao et al.
JOURNAL OF CONTROLLED RELEASE (2019)
Endoplasmic reticulum stress signalling and the pathogenesis of non-alcoholic fatty liver disease
Cynthia Lebeaupin et al.
JOURNAL OF HEPATOLOGY (2018)
Global epidemiology of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: What we need in the future
Ana Ruth Araujo et al.
LIVER INTERNATIONAL (2018)
Mechanisms of NAFLD development and therapeutic strategies
Scott L. Friedman et al.
NATURE MEDICINE (2018)
AMPK Activation Reduces Hepatic Lipid Content by Increasing Fat Oxidation In Vivo
Marc Foretz et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Curcumin-loaded galactosylated BSA nanoparticles as targeted drug delivery carriers inhibit hepatocellular carcinoma cell proliferation and migration
Yike Huang et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2018)
NAFLD and diabetes mellitus
Herbert Tilg et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2017)
Asialoglycoprotein receptor-targeted liposomes loaded with a norcantharimide derivative for hepatocyte-selective targeting
Xiaolin Liu et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2017)
AMPK: Mechanisms of Cellular Energy Sensing and Restoration of Metabolic Balance
Daniel Garcia et al.
MOLECULAR CELL (2017)
FATTY LIVER DISEASE: TURNING THE TIDE
Liam Drew
NATURE (2017)
Celastrol ameliorates liver metabolic damage caused by a high-fat diet through Sirt1
Yinliang Zhang et al.
MOLECULAR METABOLISM (2017)
The battle of nano paclitaxel
Alexandros Marios Sofias et al.
ADVANCED DRUG DELIVERY REVIEWS (2017)
Nutritional Approaches to Achieve Weight Loss in Nonalcoholic Fatty Liver Disease
Christine C. Hsu et al.
ADVANCES IN NUTRITION (2017)
Doxorubicin and paclitaxel co-bound lactosylated albumin nanoparticles having targetability to hepatocellular carcinoma
Le Quang Thao et al.
COLLOIDS AND SURFACES B-BIOINTERFACES (2017)
Cascade regulation of PPARγ2 and C/EBPα signaling pathways by celastrol impairs adipocyte differentiation and stimulates lipolysis in 3T3-L1 adipocytes
Seung Kug Choi et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2016)
Plant-derived triterpene celastrol ameliorates oxygen glucose deprivation-induced disruption of endothelial barrier assembly via inducing tight junction proteins
Dan Luo et al.
PHYTOMEDICINE (2016)
Treatment of Obesity with Celastrol
Junli Liu et al.
CELL (2015)
Celastrol Protects against Obesity and Metabolic Dysfunction through Activation of a HSF1-PGC1α Transcriptional Axis
Xinran Ma et al.
CELL METABOLISM (2015)
Asialoglycoprotein receptor mediated hepatocyte targeting - Strategies and applications
Anisha A. D'Souza et al.
JOURNAL OF CONTROLLED RELEASE (2015)
Metabolic syndrome and nonalcoholic fatty liver disease: Is insulin resistance the link?
Mohamed Asrih et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2015)
Celastrol identified as a leptin sensitizer and potential novel treatment for obesity
Claire Greenhill
Nature Reviews Endocrinology (2015)
Celastrol suppresses obesity process via increasing antioxidant capacity and improving lipid metabolism
Chaoyun Wang et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2014)
Direct comparison of two albumin-based paclitaxel-loaded nanoparticle formulations: Is the crosslinked version more advantageous?
Chunlei Li et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2014)
From NAFLD to NASH to cirrhosis - new insights into disease mechanisms
Alexander Wree et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2013)
Celastrol, an NF-κB Inhibitor, Improves Insulin Resistance and Attenuates Renal Injury in db/db Mice
Jung Eun Kim et al.
PLOS ONE (2013)
Nonalcoholic fatty liver disease: molecular mechanisms for the hepatic steatosis
Seung-Hoi Koo
CLINICAL AND MOLECULAR HEPATOLOGY (2013)
Albumin-based nanoparticles as potential controlled release drug delivery systems
Ahmed O. Elzoghby et al.
JOURNAL OF CONTROLLED RELEASE (2012)
Animal models of nonalcoholic fatty liver disease
Lionel Hebbard et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2011)
In Vitro Evaluation of Potential Hepatotoxicity Induced by Drugs
M. J. Gomez-Lechon et al.
CURRENT PHARMACEUTICAL DESIGN (2010)
Pathogenesis of non-alcoholic fatty liver disease
J. K. Dowman et al.
QJM-AN INTERNATIONAL JOURNAL OF MEDICINE (2010)
SIRT1 regulates hepatocyte lipid metabolism through activating AMP-activated protein kinase
Xiuyun Hou et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
A human hepatocellular in vitro model to investigate steatosis
Maria Jose Gomez-Lechon et al.
CHEMICO-BIOLOGICAL INTERACTIONS (2007)
Histological assessment of non-alcoholic fatty liver disease
S. G. Huebscher
HISTOPATHOLOGY (2006)
Share Paper
